Commentary: Clinical Knowledge Gaps Hinder Fight Against Smoking in Central Asia and Caucasus

Why It Matters

Without evidence‑based clinical guidance, physicians cannot effectively promote proven cessation methods, undermining regional tobacco‑control goals and prolonging preventable disease burdens.

Key Takeaways

• Over 80% of Kazakh doctors lack formal cessation training
• 94% of Kazakh physicians mistakenly link nicotine to lung cancer
• Kazakhstan bans e‑cigs, fueling doctor skepticism of harm‑reduction tools
• Only ~3% of surveyed doctors recommend non‑combustible nicotine products
• Doctors favor willpower advice; cessation success rates remain below 5%

Pulse Analysis

The legacy of Soviet‑era smoking prevalence continues to shape health outcomes across Central Asia and the Caucasus. While governments have introduced higher taxes and public‑smoking bans, the latest Healthy Initiatives survey shows that the medical workforce is ill‑equipped to translate policy into patient‑level change. In Kazakhstan, more than 80% of physicians have never undergone structured cessation training, and a staggering 94% incorrectly attribute lung cancer risk to nicotine rather than tobacco combustion. This fundamental misunderstanding skews risk communication and discourages the adoption of evidence‑based tools such as nicotine replacement therapy or reduced‑risk products.

These knowledge gaps have concrete consequences for harm‑reduction strategies that have proven successful in jurisdictions like the United Kingdom and New Zealand. The survey highlights a stark contrast between Kazakhstan and Georgia: Kazakh doctors overwhelmingly view e‑cigarettes and nicotine pouches as more harmful than traditional cigarettes, a perception reinforced by recent national bans on these products. Consequently, fewer than three percent of clinicians recommend any non‑combustible alternatives, opting instead for “cold turkey” approaches that yield quit‑rates around 3 percent. This disconnect not only limits individual cessation success but also hampers broader public‑health objectives aimed at reducing tobacco‑related mortality.

Addressing the crisis requires a two‑pronged effort. First, national health ministries must integrate modern cessation science into mandatory continuing medical education, emphasizing the distinction between nicotine addiction and combustion‑related toxicity. Second, policy frameworks should align regulatory stances with global best practices, allowing calibrated use of reduced‑risk products under clinical supervision. By closing the clinical knowledge gap, the region can leverage both behavioral counseling and pharmacological aids, ultimately accelerating declines in smoking prevalence and associated disease burden.